The global epigenetics market size reached USD 2.7 Billion in 2024. Looking forward, IMARC Group expects the market to reach USD 7.8 Billion by 2033, exhibiting a growth rate (CAGR) of 12.02% during 2025-2033.
Report Attribute
|
Key Statistics
|
---|---|
Base Year
|
2024
|
Forecast Years
|
2025-2033
|
Historical Years
|
2019-2024
|
Market Size in 2024
|
USD 2.7 Billion |
Market Forecast in 2033
|
USD 7.8 Billion |
Market Growth Rate (2025-2033) | 12.02% |
Epigenetics refers to the study of heritable changes in the expression of active and inactive genes. The sources of changes can be both external from environmental factors or internal factors, such as age and disease. It is commonly used for the diagnosis of underlying conditions and preventing them from getting transferred to the future generations. It involves the use of various enzymes, instruments, such as sequencers, spectrometers and sonicators, reagents and kits. They are commonly utilized for deoxyribonucleic acid (DNA) and histone methylation, non-coding ribonucleic acid (RNA), acetylation and phosphorylation. As a result, epigenetics is widely used for the diagnosis, monitoring and treatment of oncological, autoimmune, metabolic, cardiovascular and pain disorders.
The increasing prevalence of cancer and autoimmune deficiency syndrome (AIDS) across the globe is among the key factors driving the market growth. Moreover, the widespread adoption of epigenetic solutions for non-oncological ailments is providing a thrust to the market growth. The sudden outbreak of the coronavirus disease (COVID-19) is also providing growth opportunities to market players. For instance, various research institutes are running advanced epigenetic tests to study the impact of the virus on the human genome and are developing tools for early recognition, risk evaluations and developing personalized treatments. Additionally, the development of DNA and RNA modifying enzymes, such as acetylases, methyltransferases, reverse transcriptase and ligases, and the launch of highly sensitive and selective tests and instruments, are acting as other growth-inducing factors. These innovations facilitate the assessment of locus-specific DNA methylation on a genome. Other factors, including extensive research and development (R&D) activities in the field of biotechnology, along with significant improvements in the healthcare infrastructure, especially in the developing economies, are anticipated to drive the market toward growth.
IMARC Group provides an analysis of the key trends in each sub-segment of the global epigenetics market report, along with forecasts at the global, regional and country levels from 2025-2033. Our report has categorized the market based on product, technology, and application.
Breakup by Product:
Breakup by Technology:
Breakup by Application:
Breakup by Region:
The competitive landscape of the industry has also been examined along with the profiles of the key players being Abcam plc, Active Motif Inc., Agilent Technologies Inc., Diagenode Diagnostics (Hologic Inc), Illumina Inc., Merck KGaA, PerkinElmer Inc., Roche Holding AG, Thermo Fisher Scientific Inc. and Zymo Research Corporation.
Report Features | Details |
---|---|
Base Year of the Analysis | 2024 |
Historical Period | 2019-2024 |
Forecast Period | 2025-2033 |
Units | Billion USD |
Segment Coverage | Product, Technology, Application, Region |
Region Covered | Asia Pacific, Europe, North America, Latin America, Middle East and Africa |
Countries Covered | United States, Canada, Germany, France, United Kingdom, Italy, Spain, Russia, China, Japan, India, South Korea, Australia, Indonesia, Brazil, Mexico |
Companies Covered | Abcam plc, Active Motif Inc., Agilent Technologies Inc., Diagenode Diagnostics (Hologic Inc), Illumina Inc., Merck KGaA, PerkinElmer Inc., Roche Holding AG, Thermo Fisher Scientific Inc. and Zymo Research Corporation |
Customization Scope | 10% Free Customization |
Post-Sale Analyst Support | 10-12 Weeks |
Delivery Format | PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request) |
The global epigenetics market was valued at USD 2.7 Billion in 2024.
We expect the global epigenetics market to exhibit a CAGR of 12.02% during 2025-2033.
The rising prevalence of cancer and Autoimmune Deficiency Syndrome (AIDS), along with the increasing consumer preference towards personalized medicines, is primarily driving the global epigenetics market.
The sudden outbreak of the COVID-19 pandemic has led to the growing utilization of epigenetics tests by various research institutes to study the impact of the coronavirus infection on the human genome and develop tools for early recognition and risk evaluations.
Based on the product, the global epigenetics market can be segmented into reagents, kits, instruments, enzymes, and services. Currently, kits hold the majority of the total market share.
Based on the technology, the global epigenetics market has been divided into DNA methylation, histone methylation, histone acetylation, large non-coding RNA, microRNA modification, and chromatin structures. Among these, DNA methylation currently exhibits a clear dominance in the market.
Based on the application, the global epigenetics market can be categorized into oncology and non-oncology. Currently, oncology accounts for the largest market share.
On a regional level, the market has been classified into North America, Asia-Pacific, Europe, Latin America, and Middle East and Africa, where North America currently dominates the global market.
Some of the major players in the global epigenetics market include Abcam plc, Active Motif Inc., Agilent Technologies Inc., Diagenode Diagnostics (Hologic Inc), Illumina Inc., Merck KGaA, PerkinElmer Inc., Roche Holding AG, Thermo Fisher Scientific Inc., and Zymo Research Corporation.